Software and AI to check blocked blood flow during uterine fibroid treatment
Tests software that measures blood flow during uterine fibroid embolization procedures.
Key facts
- Who runs it
- Emanuele Barabino
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Artificial Intelligence for the Intra-procedural Assessment of Uterine Artery Embolization
- Status
- Not yet recruiting
- People taking part
- 250 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 31 May 2027
- Type of study
- Observational
- Record updated
- 19 November 2025
Who can take part
The trial is looking for women with uterine fibroids that cause symptoms, who had uterine artery embolization (UAE). UAE is a procedure that blocks the blood supply to the fibroids.
- Age
- 18 to 55 years
- Sex
- Female only
- Disease stage
- Uterine fibroids that cause symptoms, for example bleeding, pressure from their size, or pain.
- Earlier treatment
- People must have had UAE as their main, final treatment for the fibroids.
- Main reasons for not taking part
- No clinical follow-up after the procedure
- Poor quality or incomplete images of the blood vessels (angiographic images)
- For the past-data group: no baseline clinical or imaging data available
- For the new-patient group: not able to give informed consent
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- Female patients ≥18 years
- Symptomatic uterine fibroids (e.g., bleeding, bulk symptoms, pain)
- Underwent UAE as definitive therapy
- Availability of baseline clinical/imaging data (for retrospective arm) or ability to provide informed consent (for prospective arm)
Who cannot take part
- Lack of clinical follow-up
- Poor quality or incomplete angiographic images
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Uterine fibroids
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Uterine artery embolization is a minimally invasive treatment for symptomatic uterine fibroids, but intra-procedural assessment of embolization adequacy currently relies on subjective angiographic criteria. This study evaluates a proprietary angiographic analysis software (AQ-VERO) that extracts quantitative time-to-density perfusion metrics in real time. The study aims to (1) validate the accuracy and reproducibility of AQ-VERO during uterine artery mebolization, and (2) develop an AI-based decision support system using AQ-VERO-derived metrics to improve objective intra-procedural assessment of treatment endpoints.
The group in the trial
- 250 patients with a diagnosis of uterine fibroids who underwent uterine artery embolization
Women diagnosed with symptomatic uterine fibroids who underwent image-guided uterine artery embolization as treatment. No additional surgical or medical interventions were performed during the procedure.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Validation and Implementation With Artificial Intelligence of Software for the Intra-procedural Assessment of Uterine Artery EMBOlization
- Plain-language title
- Software and AI to check blocked blood flow during uterine fibroid treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07230444, who can take part
- Record updated
- 19 November 2025